Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: Bloodstream infections caused by carbapenem-resistant bacteria have increased globally. Solid-organ transplant recipients are more prone to these infections. This study aimed to compare the clinical courses of carbapenem-susceptible and carbapenem-resistant Enterobacteriaceae bloodstream infections and to identify risk factors for carbapenem resistance in solid-organ transplant recipients.

Materials And Methods: For this retrospective descriptive study, data for solid-organ transplant recipients (age ≥18) treated from 2015 to 2022 were obtained from medical records. Enterobacteriaceaepositive blood culture was screened from laboratory data.

Results: Among 72 patients, there were 100 bacteremia episodes. Patients included 40 kidney (55.6%), 21 liver (29.2%), 7 heart (9.7%), and 4 combined liver and kidney (5.6%) transplant recipients. Fifty-seven bacteremia episodes were recorded between 2015 and 2020, and 43 bacteremia episodes were recorded between 2020 and 2022. Carbapenem resistance was reported in 15.8% of patients before 2020, whereas this rate increased to 39.5% after 2020 (P = .007). Pitt bacteremia score ≥4 (P < .001), Charlson comorbidity index ≥4 (P = .021), chronic liver disease (P = .015), septic shock at admission (P = .001), hypotension at admission (P = .006), bacteremia episodes 48 hours after hospitalization (P = .004), hospitalization in the past 3 months (P = .004), and prior invasive procedure (P = .043) were significant factors for carbapenem resistance. Logistic regression analysis showed that bacteremia 48 hours after hospitalization (P = .002) and hospitalization in the past 3 months (P = .006) were independent risk factors.

Conclusions: Carbapenem resistance increased significantly over the years. Bacteremia 48 hours after hospitalization and hospitalization within the past 3 months were determined to be risk factors for carbapenem resistance. Carbapenem-resistant infections are still nosocomial infections. Patients should be hospitalized for as a short time as possible, and both patients and their physicians should follow infection control and prevention methods.

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.MESOT2023.O38DOI Listing

Publication Analysis

Top Keywords

carbapenem resistance
20
bacteremia episodes
16
solid-organ transplant
12
transplant recipients
12
factors carbapenem
12
hours hospitalization
12
hospitalization months
12
carbapenem-resistant enterobacteriaceae
8
bloodstream infections
8
risk factors
8

Similar Publications

Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice.

View Article and Find Full Text PDF

Purpose: Lung cancer is currently the most common malignant tumor worldwide and one of the leading causes of cancer-related deaths, posing a serious threat to human health. MicroRNAs (miRNAs) are a class of endogenous non-coding small RNA molecules that regulate gene expression and are involved in various biological processes associated with lung cancer. Understanding the mechanisms of lung carcinogenesis and detecting disease biomarkers may enable early diagnosis of lung cancer.

View Article and Find Full Text PDF

Increasing rates of antimicrobial resistance require additional safe and effective options for managing difficult-to-treat infections. SPR206 is a next-generation polymyxin with improved safety profiles. This study determined the activity of SPR206 against a diverse collection of gram-negative isolates.

View Article and Find Full Text PDF

Rapid detection of carbapenemases in multiresistant Gram-negative strains: evaluation of two tests.

Microbiol Spectr

September 2025

Institute for Medical Laboratory Diagnostics, Helios University Hospital, Witten/Herdecke University, Wuppertal, Germany.

Carbapenem-resistant organisms (CRO) have rapidly spread worldwide in recent years, posing a significant challenge to both human health and healthcare systems. Timely and accurate detection of CRO, especially carbapenemase-producing and non-fermenters, is crucial for clinical prevention and treatment of these infections. In the present study, we subjected more than 114 multidrug-resistant Gram-negative and non-fermenters to two tests for the timely detection of carbapenemases.

View Article and Find Full Text PDF

Carbapenemases, β-lactamases hydrolysing carbapenem antibiotics, challenge the treatment of multi-drug resistant bacteria. The OXA-48 carbapenemase is widely disseminated in , necessitating new treatments for producer strains. Diazabicyclooctane (DBO) inhibitors, including avibactam and nacubactam, act on a wide range of enzymes to overcome β-lactamase-mediated resistance.

View Article and Find Full Text PDF